United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

21 Aug 2019
Change (% chg)

$0.62 (+1.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Mayleben, Timothy 

Mr. Timothy M. Mayleben is President, Chief Executive Officer, Director at Esperion Therapeutics Inc. He has served as our President and Chief Executive Officer since December 2012 and as a member of our Board since February 2010. Prior to joining Esperion, Mr. Mayleben was President, CEO and a director of Vericel Corporation (NASDAQ: VCEL) (formerly Aastrom Biosciences). Previously, Mr. Mayleben was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, he was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma and Marinus Pharmaceuticals (NASDAQ: MRNS) as well as the Wolverine Venture Fund. Mr. Mayleben previously served as a director of Loxo Oncology, Inc. (NASDAQ: LOXO) prior to its acquisition by Eli Lilly. Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business. We believe that Mr. Mayleben's experience working in the life sciences industry, including over a decade of experience as an executive officer of several life sciences companies, qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD 715,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 9,009,840
Fiscal Year Total, USD 9,724,840

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 4,549 324,534.00
Name Fiscal Year Total

Timothy Mayleben


Richard Bartram


Narendra Lalwani


Mark Glickman


Nicole Vitullo


Jeffrey Berkowitz

As Of  31 Dec 2018